Citraconic acid Clinical Trials

Size	Price	Qty
100mg	USD 97

Clinical Trials

Several clinical trials evaluate this compound across diverse indications, including solid tumors such as recurrent and stage I through IV uterine corpus carcinoma and Lynch syndrome, surgical recovery in colorectal disorders, and adolescent post-traumatic stress disorder. Sponsored by institutions including the National Cancer Institute, the Gynecologic Oncology Group Foundation, the University of Alabama at Birmingham, and the University of California Los Angeles, these studies encompass Phase 2, non-applicable, and unassigned phase designs. Currently, all of these trials maintain a recruitment status of not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01199250	Not yet recruiting	Lynch Syndrome\|Recurrent Uterine Corpus Carcinoma\|Stage I Uterine Corpus Cancer\|Stage II Uterine Corpus Cancer\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	2100-01	--
NCT01164735	Not yet recruiting	Recurrent Uterine Corpus Carcinoma\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	2100-01	--
NCT06356558	Not yet recruiting	Surgery\|Health Knowledge Attitudes Practice\|Colorectal Disorders	University of Alabama at Birmingham\|National Cancer Institute (NCI)	2026-05	Not Applicable
NCT06353282	Not yet recruiting	PTSD Post Traumatic Stress Disorder\|Adolescents\|Psychotherapy	University of California Los Angeles	2025-07-01	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Citraconic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Citraconic acid selectively interacts with enzymes governing branched-chain fatty acid metabolism, disrupting downstream cellular lipid synthesis and impairing critical energy production pathways within target cells. This metabolic inhibition suppresses energy-dependent cellular viability and proliferation, providing key mechanistic insight into targeting aggressive neoplastic growth such as uterine corpus carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).